Imricor Medical Systems expands its US market reach with FDA 510(k) clearances for pediatric use of its NorthStar system and Vision-MR Diagnostic Catheter, enabling radiation-free cardiac catheterisations for children.
- FDA clears NorthStar and Vision-MR for pediatric use
- Radiation-free iMR procedures target vulnerable children
- Over 250,000 cardiac catheterisations annually in US
- Pediatric market seen as early commercial channel
- Supports broader US commercialization strategy
FDA Clears Pediatric Use for Imricor’s iMR Devices
Imricor Medical Systems (ASX:IMR) has landed a significant regulatory milestone with the FDA granting 510(k) clearances to expand its NorthStar® Mapping System and Vision-MR® Diagnostic Catheter labeling to include pediatric patients. This development opens the door for radiation-free interventional magnetic resonance (iMR) guided cardiac catheterisations in children, a patient group highly sensitive to ionising x-ray exposure.
The clearances come just months after NorthStar received FDA approval for adult use earlier this year and follow the company’s April submission for pediatric labeling expansion. Imricor strategically included the Vision-MR Diagnostic Catheter in the pediatric application during discussions with the FDA, aiming to offer a more comprehensive suite of iMR devices for children and young adults.
Targeting Pediatric Cardiac Catheterisations
With more than 250,000 diagnostic right and left heart catheterisations performed annually across US hospitals, including over 250 children’s hospitals, the pediatric market represents a substantial opportunity. Children born with congenital heart defects often require multiple cardiac catheterisations early in life, exposing them repeatedly to x-ray radiation. Imricor’s iMR technology eliminates all procedure-related x-rays, potentially reducing long-term radiation risks for this vulnerable population.
NorthStar, the world’s first and only MR-native 3D iMR mapping and guidance system, combined with the Vision-MR Diagnostic Catheter, offers a novel workflow where MRI imaging and interventional procedures can be performed seamlessly in the iMR lab. This contrasts with traditional approaches requiring separate MRI scans followed by x-ray-guided interventions, delivering potential time and cost savings to hospitals.
Strategic Commercial Implications for Imricor
Imricor views the pediatric segment as a strategic early commercial channel ahead of wider adoption of its full electrophysiology platform in adult hospitals. Children’s hospitals tend to prioritise reducing radiation exposure and contrast dye use, making them receptive to iMR solutions that can improve procedural workflows. The Vision-MR Diagnostic Catheter will further enhance diagnostic electrophysiological applications once the Advantage-MR EP Recorder/Stimulator receives FDA clearance.
Steve Wedan, Imricor’s Chair and CEO, emphasised the company’s commitment to delivering radiation-free iMR procedures across all patient groups, highlighting the personal and professional rewards of advancing pediatric interventional medicine.
Bottom Line?
Imricor’s pediatric FDA clearances mark a pivotal step in expanding its US footprint, but the pace of adoption in children’s hospitals and subsequent approvals for complementary devices will be key to unlocking commercial potential.
Questions in the middle?
- How quickly will children’s hospitals integrate iMR-guided catheterisations into standard practice?
- What impact will the pending FDA clearance of the Advantage-MR EP Recorder/Stimulator have on diagnostic applications?
- Can Imricor leverage pediatric adoption to accelerate broader adult hospital uptake of its full EP platform?